MoneyWorks4Me

Medicamen Biotech signs contract for CDMO with XGX pharma

03 Apr 2025 Evaluate

Medicamen Biotech has signed a contract for CDMO with XGX pharma, European company where Medicamen will develop 6 products and will do manufacturing of these products for European company. XGX will hold MA (Market authorisation).

Earlier, the company had entered into an understanding with a prominent South African business conglomerate for registering and marketing its products in the region. South Africa represents a $4 billion pharmaceutical market and is categorized as a regulated market.

Medicamen Biotech is engaged in manufacturing and marketing of pharmaceutical formulations in overseas and domestic markets.

Medicamen Biotech Share Price

242.75 6.00 (2.53%)
13-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1942.85
Dr. Reddys Labs. 1206.00
Cipla 1461.00
Lupin 2261.00
Zydus Lifesciences 1173.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: